金城医药 (300233.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(金城医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年第四季度2023年第三季度2023年第二季度2023年第一季度2022年第四季度2022年第三季度2022年第二季度2022年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 969,559,792.08863,459,370.88875,766,754.69829,526,542.00914,461,792.71739,470,118.84898,722,851.51953,062,199.12
 营业收入(元) 969,559,792.08863,459,370.88875,766,754.69829,526,542.00914,461,792.71739,470,118.84898,722,851.51953,062,199.12
二、营业总成本(元) 906,918,277.17816,266,241.44805,283,369.21765,199,920.75850,037,332.94702,691,780.18769,945,458.87810,774,617.57
 营业成本(元) 509,889,716.78511,516,405.82494,297,650.87475,423,314.44507,628,523.05350,701,291.78485,447,048.80541,478,840.35
 研发费用(元) 62,885,353.8945,619,032.6247,701,744.1328,502,407.6165,050,203.7631,365,887.9231,452,396.2043,235,054.66
 营业税金及附加(元) 8,058,082.839,791,922.449,243,528.209,061,715.287,836,339.738,182,512.437,733,712.649,297,897.93
 销售费用(元) 190,807,741.91174,274,128.30165,253,564.87150,312,138.72195,984,798.18174,586,563.56127,742,911.90130,277,440.43
 管理费用(元) 134,291,325.0672,206,479.5390,317,819.8393,935,166.6264,143,907.63135,588,990.89118,747,280.0982,262,956.91
 财务费用(元) 986,056.702,858,272.73-1,530,938.697,965,178.089,393,560.592,266,533.60-1,177,890.764,222,427.29
  其中:利息费用(元) 5,732,063.175,721,311.726,796,056.396,674,810.488,501,218.165,076,080.957,994,067.155,252,638.36
  其中:利息收入(元) 5,149,697.783,394,626.032,722,107.123,326,254.193,050,755.613,238,690.203,615,696.842,350,209.60
 资产减值损失(元) -28,001,346.10-11,057,346.11-7,435,727.62-48,413.87-41,973,817.94-617,258.40--
 信用减值损失(元) -2,968,193.16-851,750.32417,933.92-1,405,326.19-8,821,501.5811,883,251.61-135,446.68-4,257,894.66
三、其他经营收益
 加:公允价值变动收益(元) -68,128.87251,042.2570,231.49-334,685.44-233,189.90-1,154,363.3860,402.30843,584.31
 加:投资收益(元) 660,499.47262,748.62-316,723.23-16,391.9177,986.712,242,654.51304,681.38818,888.46
  其中:对联营企业和合营企业的投资收益(元) -486,660.77-86,922.2288,879.53-245,794.05-204,373.15-225,845.78--
 资产处置收益(元) 455,574.71228,851.71-2,465,999.57-374,726.61-2,866,798.5139,042.083,828,473.59524,542.58
 其他收益(元) 17,612,957.175,315,478.974,673,531.936,600,474.574,225,747.495,770,571.974,180,033.314,948,549.71
四、营业利润(元) 50,332,878.1341,342,154.5665,426,632.4068,747,551.8014,832,886.0454,942,237.05138,836,901.07145,165,251.95
 加:营业外收入(元) 210,430.5547,550.1471,968.66654,021.973,080,450.511,062,197.691,093,598.91421,432.49
 减:营业外支出(元) 1,437,146.12780,679.8642,970.68-835,148.40295,148.30522,766.8211,301,332.701,349,721.49
五、利润总额(元) 49,106,162.5640,609,024.8465,455,630.3870,236,722.1717,618,188.2555,481,667.92128,629,167.28144,236,962.95
 减:所得税费用(元) 2,450,186.634,726,562.519,562,738.5015,357,053.20-1,166,817.0212,599,527.2620,488,655.6328,170,388.87
六、净利润(元) 46,655,975.9335,882,462.3355,892,891.8854,879,668.9718,785,005.2742,882,140.66108,140,511.65116,066,574.08
(一)按经营持续性分类
  持续经营净利润(元) 46,655,975.9335,882,462.3355,892,891.8854,879,668.9718,785,005.2742,882,140.66108,140,511.65116,066,574.08
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 42,229,002.2330,770,938.8551,554,761.8050,154,655.3314,970,165.0239,423,509.54106,492,018.27112,478,901.17
  少数股东损益(元) 4,426,973.705,111,523.484,338,130.084,725,013.643,814,840.253,458,631.121,648,493.383,587,672.91
 扣除非经常性损益后的净利润(元) 38,798,000.8926,972,232.9949,507,576.3842,904,904.3211,198,126.5334,215,800.49109,729,964.63109,032,761.00
七、每股收益
 一、基本每股收益(元) 0.110.080.130.130.040.100.280.29
 二、稀释每股收益(元) 0.110.080.130.130.040.100.280.29
八、其他综合收益(元) -5,351,471.52-1,545,441.725,511,232.38----
 归属于母公司股东的其他综合收益(元) -5,351,471.52-1,545,441.725,511,232.38----
九、综合收益总额(元) 41,304,504.4135,882,462.3357,438,333.6060,390,901.3518,785,005.2742,882,140.66108,140,511.65116,066,574.08
 归属于母公司所有者的综合收益总额(元) 36,877,530.7130,770,938.8553,100,203.5255,665,887.7114,970,165.0239,423,509.54106,492,018.27112,478,901.17
 归属于少数股东的综合收益总额(元) 4,426,973.705,111,523.484,338,130.084,725,013.643,814,840.253,458,631.121,648,493.383,587,672.91
公告日期 2024-03-292023-10-252023-08-192023-04-272023-03-312022-10-262022-08-252022-04-29
审计意见(境内) 标准无保留意见标准无保留意见

前瞻产业研究院